Skip to search formSkip to main contentSkip to account menu

Erivedge

National Institutes of Health

Related topics

Related topics

3 relations
Erivedge Pill

Broader (2)

HhAntag691vismodegib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Efficacy and safety profile of vismodegib in a real‐world setting cohort of patients with advanced basal cell carcinoma in Argentina
Vismodegib (Erivedge®), a hedgehog pathway inhibitor, is approved to treat metastatic or locally advanced basal cell carcinoma… 
2019
2019
Nanoformulation for potential topical delivery of Vismodegib in skin cancer treatment.
Review
2018
Review
2018
Traitement médical des carcinomes basocellulaires avancés
Review
2017
Review
2017
Hepatotoxicity with Vismodegib: An MD Anderson Cancer Center and Research on Adverse Drug Events and Reports Project
BackgroundOn 30 January 2012, the US FDA approved vismodegib (Erivedge®, Genentech, CA, USA) for the management of both… 
Review
2017
Review
2017
Additional Risk Minimisation Measures for Medicinal Products in the European Union: A Review of the Implementation and Effectiveness of Measures in the United Kingdom by One Marketing Authorisation…
IntroductionAdditional risk minimisation measures (aRMMs) for medicinal products are necessary to address specific important… 
2014
2014
Embryofetal development study of vismodegib, a hedgehog pathway inhibitor, in rats.
Vismodegib (Erivedge) is a first-in-class small-molecule hedgehog pathway inhibitor for the treatment of adults with advanced… 
Review
2014
Review
2014
Efficacy and safety of vismodegib: a new therapeutic agent in the treatment of basal cell carcinoma
Introduction: Basal cell carcinoma (BCC) is the most common human malignancy. Treatment options for the minority of patients… 
2012
2012
Vismodegib (erivedge) for advanced Basal cell carcinoma.
Vismodegib (Erivedge) for advanced basal cell carcinoma. 
2012
2012
Hedgehog hopes lifted by approval... and stung by failure
Review
2012
Review
2012
Efficacy and Safety of the Hedgehog Pathway Inhibitor Vismodegib in Patients with Advanced Basal Cell Carcinoma (BCC): 12-Month Erivance BCC Study Update
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)